While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Nature is its own most incorrigible plagiarist; echoes of the same aesthetic motifs show up in all kinds of places and all kinds of scales. Here, the finned texture resembles the underside of a ...

Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. Who doesn’t love a good math holiday? Most people know about Pi ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The amount of noise The Row’s annual sample sale generated last weekend was perhaps antithetical to the brand’s ultimate quiet luxury status. But what else could be expected? The brand’s legions of ...

Eleanor has an undergraduate degree in zoology from the University of Reading and a master’s in wildlife documentary production from the University of Salford. Eleanor has an undergraduate degree in ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...